Macleods Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Macleods Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 64 Products, $589.8M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Macleods Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 64 Products, $589.8M Trade | TransData Nexus

Macleods Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Tuberculosis Medications Specialist · $589.8M Total Trade · DGFT Verified

Macleods Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $589.8M across 64 products in 20 therapeutic categories. Based on 13,039 verified export shipments from Indian Customs (DGFT) records, Macleods Pharmaceuticals Limited is the #1 Indian exporter in 10 products including Tenofovir, Dolutegravir, Levothyroxine. Top exports include Isoniazid ($93.5M), Rifampicin ($82.5M), Tenofovir ($37.4M).

Macleods Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Macleods Pharmaceuticals Limited pharmaceutical export portfolio — 64 products across 20 therapeutic categories. Source: Indian Customs (DGFT).

Who is Macleods Pharmaceuticals Limited? — Company Overview & Market Position

Macleods Pharmaceuticals Limited, established in 1989, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of a diverse range of finished pharmaceutical formulations. The company's registered office is located at 304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai, Maharashtra, India, 400059. As of March 2026, Macleods Pharmaceuticals Limited operates as a public unlisted company with a Corporate Identification Number (CIN) of U24239MH1989PLC052049. The company is privately held, with authorized capital of ₹65,00,00,000 and paid-up capital of ₹59,88,20,400. Macleods Pharmaceuticals Limited employs over 10,941 individuals, reflecting its significant presence in the pharmaceutical industry. The company's official website is www.macleodspharma.com.

What Does Macleods Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Isoniazid$93.5M 2Rifampicin$82.5M

Product Portfolio — Top 30 by Export Value

Macleods Pharmaceuticals Limited exports 64 pharmaceutical products across 20 therapeutic categories. Market leader (#1 exporter) in 10 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Isoniazid	Tuberculosis Medications	$93.5M	1,870	3.1%	2
2	Rifampicin	Advanced Antibiotics	$82.5M	1,667	4.7%	2
3	Tenofovir	Antiviral & HIV Medications	$37.4M	747	0.6%	1
4	Valsartan	Cardiovascular	$32.6M	764	14.2%	2
5	Artemether	Antimalarial & Antiparasitic	$30.7M	614	2.8%	2
6	Hydrochlorothiazide	Diuretics	$29.4M	697	6.3%	2
7	Pyrazinamide	Tuberculosis Medications	$25.2M	504	1.9%	2
8	Dolutegravir	Antiviral & HIV Medications	$23.5M	470	0.4%	1
9	Ethambutol	Tuberculosis Medications	$19.8M	396	1.2%	2
10	Emtricitabine	Antiviral & HIV Medications	$18.2M	387	11.7%	2
11	Amlodipine	Cardiovascular	$17.5M	350	0.2%	6
12	Levothyroxine	Diabetes & Endocrine	$13.9M	278	17.9%	1
13	Irbesartan	Cardiovascular	$12.5M	267	8.4%	1
14	Ofloxacin	Advanced Antibiotics	$12.2M	243	4.1%	3
15	Montelukast	Respiratory	$11.6M	231	6.9%	1
16	Levofloxacin	Antibiotics	$11.0M	318	13.2%	1
17	Clopidogrel	Cardiovascular	$9.5M	190	3.8%	2
18	Celecoxib	Analgesics & Antipyretics	$9.2M	184	6.9%	2
19	Efavirenz	Antivirals	$8.6M	177	10.1%	1
20	Rosuvastatin	Cardiovascular	$8.4M	207	1.8%	12
21	Pantoprazole	Gastrointestinal	$7.3M	165	0.5%	10
22	Sodium	Nutritional Supplements	$6.7M	133	1.6%	10
23	Oseltamivir	Antivirals	$6.3M	127	3.8%	8
24	Apixaban	Cardiovascular	$5.1M	102	2.4%	1
25	Linezolid	Advanced Antibiotics	$4.8M	96	9.7%	1
26	Artesunate	Antimalarial & Antiparasitic	$4.8M	95	2.8%	3
27	Pioglitazone	Diabetes & Endocrine	$4.6M	417	8.9%	4
28	Azithromycin	Antibiotics	$4.5M	91	2.5%	10
29	Cefixime	Advanced Antibiotics	$3.3M	65	1.9%	10
30	Ras	Ayurvedic & Herbal Products	$3.2M	64	1.0%	12

Macleods Pharmaceuticals Limited exports 64 pharmaceutical products across 20 therapeutic categories with a total export value of $589.8M. The company is the #1 Indian exporter in 10 products: Tenofovir, Dolutegravir, Levothyroxine, Irbesartan, Montelukast and 4 more. The top category is Tuberculosis Medications (23.5% of portfolio), followed by Advanced Antibiotics (17.9%), reflecting a diversified portfolio where the top 5 products account for only 46.9% of total value.

Showing top 30 of 64 products. Contact us for complete data.

Macleods Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Macleods Pharmaceuticals Limited operates multiple manufacturing facilities across India, including locations in Daman, Baddi, Sikkim, and Indore. (intuitionlabs.ai) These facilities are approved by various regulatory authorities, such as the US FDA, UK MHRA, and WHO, ensuring compliance with international standards. (intuitionlabs.ai) The company's manufacturing plants are equipped to produce a wide array of pharmaceutical products, including solid and liquid oral formulations, injectables, and inhalers. This extensive manufacturing capability supports Macleods Pharmaceuticals Limited's global distribution network.

3Key Leadership

The leadership team at Macleods Pharmaceuticals Limited is headed by Managing Director Dr. Rajendra Agarwal, who also serves as the founder of the company. Other key executives include Banwarilal Murlidhar Bawri, Girdharilal Murlidhar Bawri, Mihir Bipin Shah, Arvind Sadashiv Mokashi, and Vinita Mayur Danait. These leaders bring a wealth of experience and expertise to the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Macleods Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Macleods Pharmaceuticals Limited has established a strong presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has received approvals from the US FDA for over 150 products, demonstrating its commitment to meeting stringent regulatory standards. (intuitionlabs.ai) In the European Union, Macleods Pharmaceuticals Limited has obtained approximately 40 approvals, reflecting its adherence to EU regulatory requirements. (intuitionlabs.ai) The company's manufacturing facilities are approved by the UK MHRA and WHO, further validating the quality and compliance of its products. (intuitionlabs.ai) These approvals facilitate Macleods Pharmaceuticals Limited's market access and distribution in these key regions.

2Emerging Markets

Macleods Pharmaceuticals Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), enabling access to these regions and supporting global health initiatives. This WHO prequalification underscores the company's commitment to providing high-quality, affordable medicines to diverse populations.

3Geographic Strategy

Macleods Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Macleods Pharmaceuticals Limited has a robust relationship with the US Food and Drug Administration (FDA). The company has received approvals for over 150 products, indicating a strong portfolio in the US market. (intuitionlabs.ai) Additionally, Macleods Pharmaceuticals Limited has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), demonstrating its active engagement in the US regulatory process. The company's manufacturing facilities have undergone FDA inspections, resulting in favorable outcomes, which attest to the quality and compliance of its operations.

2WHO & EU GMP

Macleods Pharmaceuticals Limited's commitment to quality is evidenced by its WHO prequalification status, which facilitates access to global markets and supports international health initiatives. The company's manufacturing facilities are certified with EU Good Manufacturing Practice (GMP) certificates, ensuring adherence to European regulatory standards. These certifications reflect Macleods Pharmaceuticals Limited's dedication to maintaining high-quality manufacturing processes across its operations.

3CDSCO & Indian Regulatory

Macleods Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Macleods Pharmaceuticals Limited operates in a competitive landscape alongside other major Indian pharmaceutical companies such as Sun Pharmaceutical Industries, Lupin Limited, Cipla, Aurobindo Pharma, and Dr. Reddy's Laboratories. In the therapeutic category of anti-tuberculosis medications, Macleods Pharmaceuticals Limited holds a significant market share, reflecting its leadership in this segment. The company's diverse product portfolio and global presence position it competitively within the industry.

2Key Differentiators

Macleods Pharmaceuticals Limited's key differentiators include its extensive product portfolio, which spans various therapeutic areas such as anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatments. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, UK MHRA, and WHO, underscoring its commitment to quality and compliance. Additionally, Macleods Pharmaceuticals Limited's focus on research and development, with over 1,900 scientists and multiple DSIR-approved research centers, enables it to innovate and expand its product offerings effectively. (intuitionlabs.ai)

3Strategic Position

Buyer Due Diligence Brief — Evaluating Macleods Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Macleods Pharmaceuticals Limited has a strong track record in the pharmaceutical industry, with a total export value of $589.8 million USD and 13,039 shipments across 64 products in 20 therapeutic categories. The company's top five products—Tenofovir, Dolutegravir, Levothyroxine, Irbesartan, and Montelukast—demonstrate its leadership in various therapeutic segments. The company's manufacturing facilities are approved by multiple international regulatory bodies, including the US FDA, UK MHRA, and WHO, ensuring compliance with global standards. Macleods Pharmaceuticals Limited's commitment to quality and regulatory compliance makes it a reliable supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering Macleods Pharmaceuticals Limited as a supplier:

FDA Approval: Confirm that the company's products are approved by the US Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the company's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practice (GMP) program. This information is typically available on the WHO's official website.

Frequently Asked Questions — Macleods Pharmaceuticals Limited

How many pharmaceutical products does Macleods Pharmaceuticals Limited export from India?

Macleods Pharmaceuticals Limited exports 64 pharmaceutical products across 20 therapeutic categories. The top exports are Isoniazid ($93.5M), Rifampicin ($82.5M), Tenofovir ($37.4M), Valsartan ($32.6M), Artemether ($30.7M). Total export value is $589.8M.

What is Macleods Pharmaceuticals Limited's total pharmaceutical export value?

Macleods Pharmaceuticals Limited's total pharmaceutical export value is $589.8M, based on 13,039 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Macleods Pharmaceuticals Limited the #1 Indian exporter?

Macleods Pharmaceuticals Limited is the #1 Indian exporter in 10 products: Tenofovir (0.6% market share), Dolutegravir (0.4% market share), Levothyroxine (17.9% market share), Irbesartan (8.4% market share), Montelukast (6.9% market share), Levofloxacin (13.2% market share), Efavirenz (10.1% market share), Apixaban (2.4% market share), Linezolid (9.7% market share).

What therapeutic categories does Macleods Pharmaceuticals Limited cover?

Macleods Pharmaceuticals Limited exports across 20 therapeutic categories. The largest are Tuberculosis Medications (23.5%, 3 products), Advanced Antibiotics (17.9%, 8 products), Cardiovascular (14.6%, 8 products).

Get Full Macleods Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.